Publications

Home » Pipeline » Publications
Publications

At Versartis, we’re committed to conducting research to guide and validate our treatment approaches, and to sharing what we’ve learned with the medical community through publications and at scientific forums. Read about our original research into the treatment of endocrine disorders with some of the world’s leading professionals in the field of endocrinology by clicking the links below.

ECE 2017

3-Year Safety and Efficacy Update of the VERTICAL & VISTA Trials of Somavaratan (VRS-317), a Long-Acting rhGH, in Children with Growth Hormone Deficiency (GHD). 19th European Congress of Endocrinology. Lisbon, Portugal.

Poster

ENDO 2017

Safety and Efficacy of Somavaratan (VRS-317), a Long-Acting Recombinant Human Growth Hormone (rhGH), in Children with Growth Hormone Deficiency (GHD): 3-Year Update of the VERTICAL & VISTA Trials (NCT01718041, NCT02068521). Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Oral Presentation

Somavaratan, a Long-Acting Recombinant Human Growth Hormone (rhGH), for the Treatment of Adults with Growth Hormone Deficiency (AGHD): Results of VITAL, an Open-Label, Dose-Finding, International, Phase 2 Study (NCT02526420). Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Oral Presentation

Achievement of a Suitable Basis of Comparison in Phase 2 and Phase 3 Pediatric Somavaratan Clinical Trials (VERTICAL, VISTA, and VELOCITY Studies) and for the Comparison of Somavaratan to Daily Recombinant Human Growth Hormone (rhGH). Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Poster

Pharmacokinetic and Pharmacodynamic (PK/PD) Analysis of Somavaratan (VRS-317), a Long-Acting Recombinant Human Growth Hormone (rhGH), in Japanese and US Children with Growth Hormone Deficiency (GHD). Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Poster

IGF Family Biomarkers in the Diagnosis of Pediatric Growth Hormone Deficiency (PGHD) in Somavaratan Clinical Trials. Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Poster

Correlation Between Baseline IGF-I, Dose, and Response to Once-Monthly Somavaratan, a Long-Acting Recombinant Human Growth Hormone (rhGH), in the Open-Label, Dose-Finding, International, Phase 2 VITAL Study in Adults with Growth Hormone Deficiency (AGHD) (NCT02526420). Presented at Endocrine Society’s 99th Annual Meeting & Expo. Orlando, Florida.

Poster

GRS 2016

Charlton RW, et al. (2016). Results of Somavaratan (VRS-317) Dose Increase in the First Two Years of Treatment in Pre-Pubertal Children with Growth Hormone Deficiency (GHD). Presented at 8th International Congress of the GRS and IGF Society. Tel Aviv.
Oral Presentation

Charlton RW, et al. (2016). Safety Profile of Somavaratan (VRS-317), a Novel Long-Acting rhGH Fusion Protein, in Pre-Pubertal Children with Growth Hormone Deficiency (GHD). Presented at 8th International Congress of the GRS and IGF Society. Tel Aviv.
Poster

ESPE 2016

Humphriss E, et al. (2016). Adherence with Twice-Monthly, At-Home Dosing Schedule of Somavaratan (VRS-317) Long-Acting Growth Hormone Treatment in Children with Growth Hormone Deficiency (GHD) in the VISTA Study (NCT02068521). Poster session presented at 55th Annual Meeting of the European Society for Paediatric Endocrinology. Paris, France.

Poster

Bright G, et al. (2016). Somavaratan (VRS-317) Treatment of Children with Growth Hormone Deficiency (GHD): VISTA Study Results at 2.5 Years (NCT02068521). Presented at 55th Annual Meeting of the European Society for Paediatric Endocrinology. Paris, France.

Poster | Oral Presentation

ICE-CSE 2016

Bright G, et al. (2016). Somavaratan (VRS-317) Treatment for Pediatric Growth Hormone Deficiency (GHD): VISTA Study Results at 2.5 Years (NCT02068521). Oral session presented at 17th International Congress of Endocrinology in collaboration with the 15th Annual Meeting of the Chinese Society of Endocrinology. Beijing, China.

Oral Presentation

Humphriss E, et al. (2016). Treatment Adherence with Weekly, Twice-Monthly and Monthly Dosing of Somavaratan (VRS-317), a Long-Acting Growth Hormone Treatment for Children with Growth Hormone Deficiency (GHD), After 24 Months of At-Home Dosing in the VISTA Study. Oral session presented at 17th International Congress of Endocrinology in collaboration with the 15th Annual Meeting of the Chinese Society of Endocrinology. Beijing, China.

Oral Presentation

Charlton, RW, et al. (2016). HbA1c over Two Years of Treatment with Somavaratan (VRS-317) in Children with Growth Hormone Deficiency (GHD) in the VISTA Study. Oral session presented at 17th International Congress of Endocrinology in collaboration with the 15th Annual Meeting of the Chinese Society of Endocrinology. Beijing, China.

Oral Presentation

Moore W, et al. (2016). A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
The Journal of Clinical Endocrinology & Metabolism. 101:3, 1091-1097. March 2016.

Yuen KC, et al. (2013). A long-acting human growth hormone with delayed clearance (VRS-317): Results of a double-blind, placebo-controlled, single ascending dose study in growth hormone deficient adults.
The Journal of Clinical Endocrinology & Metabolism 98, 2595-2603.

Cleland JL, et al. (2012). A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life.
Journal of Pharmaceutical Sciences, Vol. 101, No.8, August 2012.

Schellenberger V, et al. (2009) A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner.
Nature Biotechnology 27(12):1186-90.

Bakker B, et al. (2008) Height velocity in short children during second and third year of growth hormone (GH) treatment: Data from the National Cooperative Growth Study.
Hormone Research, Vol. 97(supplement 1):P2-d1-327.

Rosenfeld RG and Bakker B. (2008) Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract. 2008;14(2)143-54.